Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas
Open accessPublished version of a preprint
Abstract
Aberrant chromatin remodeling and activation of the PI3K pathway have been identified as important mediators of pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) pathogenesis. As inhibition of these pathways are promising therapeutic avenues and radiation is the only modality to prolong survival of patients with DIPG, we sought to explore radiosensitizing functions of such inhibition and to explore mechanisms of action of such agents. Here, we demonstrate that combined treatment with radiotherapy and CUDC-907, a novel first-in-class dual inhibitor of histone deacetylases (HDAC) and PI3K, evokes a potent cytotoxic response in pHGG and DIPG models. CUDC-907 modulated DNA damage response by inhibiting radiation-induced DNA repair pathways including homologous recombination and nonhomologous end joining. The radiosensitizing effects of CUDC-907 were mediated by decreased NFκB/Forkhead box M1 (FOXM1) recruitment to promoters of genes involved in the DNA damage response; exogenous expression of NFκB/FOXM1 protected from CUDC-907–induced cytotoxicity. Together, these findings reveal CUDC-907 as a novel radiosensitizer with potent antitumor activity in pHGG and DIPG and provide a preclinical rationale for the combination of CUDC-907 with radiotherapy as a novel therapeutic strategy against pHGG and DIPG. More globally, we have identified NFκB and FOXM1 and their downstream transcriptional elements as critical targets for new treatments for pHGG and DIPG. Significance: These findings describe the radiosensitizing effect of a novel agent in pediatric high-grade gliomas, addressing a critical unmet need of increasing the radiation sensitivity of these highly aggressive tumors. Cancer Res; 78(14); 4007–21. ©2018 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CUDC-907, a dual inhibitor of HDAC and PI3K, can induce mut-p53 degradation and abolish NFκB- and FOXM1-mediated DNA damage response to radio-sensitize pediatric high-grade glioblastomas.
“CUDC-907, a dual inhibitor of HDAC and PI3K, can induce mut-p53 degradation and abolish NFκB- and FOXM1-mediated DNA damage response to radio-sensitize pediatric high-grade GBMs [138].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [138]
The Results sections on DNA damage response and NFκB/FOXM1 activity support that CUDC-907 inhibits these pathways and radiosensitizes pediatric high-grade glioma models; the Discussion identifies it as a dual PI3K/HDAC inhibitor. Our copy does not report that CUDC-907 induces mutant-p53 degradation (searched: mut-p53 degradation, mutant p53 protein degradation, TP53). The evidence concerns glioma models, not an established clinical effect in patients. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 55 · Cited by 101
- Authors
- Pal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., Truffaux, N., Weiss, W. A., Resnick, A. C., Bandopadhayay, P., Ligon, K. L., DuBois, S. G., Mueller, S., Chowdhury, D., & Haas-Kogan, D. A.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of California, San Francisco (US)
- Harvard University (US)
- 7Department of Neurosurgery, University of California, San Francisco, San Francisco, California.
- Children's Hospital of Philadelphia (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2018-07-15
- Volume
- 78
- Issue
- 14
- Pages
- 4007-4021
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC6294442
- OpenAlex
- W2804618430
- Cited by
- 101
- References
- 55
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 18 · 2023: 13 · 2022: 9 · 2021: 17 · 2020: 21 · 2019: 6 · 2018: 1
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- NIH Brain Tumor SPORE grant (P50 CA097257)
- Topics
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- pediatric high-grade glioma, diffuse intrinsic pontine glioma, radiosensitization, CUDC-907, histone deacetylase inhibition, PI3K inhibition, NF-κB, FOXM1, DNA damage response, homologous recombination, non-homologous end joining, DNA repair, chromatin remodeling, combined radiotherapy
- MeSH terms
- Forkhead Box Protein M1, Phosphoinositide-3 Kinase Inhibitors, Animals, Brain Neoplasms, Child, DNA Damage, DNA Repair, Glioma, Histone Deacetylases, Humans, Mice, Nude, Morpholines, Pyrimidines, Radiation-Sensitizing Agents, NF-kappa B, Cell Line, Tumor, Mice, Histone Deacetylase Inhibitors, Homologous Recombination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review